Janssen announces U.S. FDA approval of PONVORY
TITUSVILLE, N.J. —The Janssen Pharmaceutical Companies of Johnson & Johnson announced Friday that the U.S. Food and Drug Administration (FDA) approved PONVORY (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. PONVORY
